

EUROPEAN PATENT APPLICATION

Application number: 85115142.3

Date of filing: 29.11.85

Int. Cl.⁴: **C 07 C 143/78**
 C 07 C 143/80, C 07 K 5/06
 C 07 K 5/08, C 07 D 211/16
 C 07 D 211/42, C 07 D 213/34
 C 07 D 213/40, C 07 D 215/06
 C 07 D 215/36, C 07 D 215/08

Priority: 30.11.84 JP 251985/84
 15.02.85 JP 26556/85
 22.03.85 JP 56153/85
 02.07.85 JP 143852/85

Date of publication of application:
 04.06.86 Bulletin 86/23

Designated Contracting States:
 CH DE FR GB LI SE

Applicant: Okamoto, Shosuke
 15-18, Asahigaoka 3-chome Tarumi-ku
 Kobe-shi Hyogo(JP)

Applicant: SHOWA DENKO K.K.
 13-9, Shiba Daimon 1-chome
 Minato-ku, Tokyo 105(JP)

Inventor: Okamoto, Shosuke
 15-18, Asahigaoka 3-chome Tarumi-ku
 Kobe-shi Hyogo(JP)

Inventor: Okada, Yoshio
 542-1, Aza Shimizu Okuradani
 Akashi-shi Hyogo(JP)

Inventor: Okunomiya, Akiko
 13-2, Nakayamatedori 7-chome Chuo-ku
 Kobe-shi Hyogo(JP)

Inventor: Naito, Taketoshi SHOWA DENKO K.K.
 Seikagakukenkyusho 24-25, Tamagawa 2-chome
 Ota-ku Tokyo(JP)

Inventor: Yamada, Morihiko SHOWA DENKO K.K.
 Seikagakukenkyusho 24-25, Tamagawa 2-chome
 Ota-ku Tokyo(JP)

Inventor: Kimura, Yoshio SHOWA DENKO K.K.
 Seikagakukenkyusho 24-25, Tamagawa 2-chome
 Ota-ku Tokyo(JP)

Inventor: Katsuura, Yasuhiro SHOWA DENKO K.K.
 Seikagakukenkyusho 24-25, Tamagawa 2-chome
 Ota-ku Tokyo(JP)

Inventor: Suzuki, Hiroshi SHOWA DENKO K.K.
 Seikagakukenkyusho 24-25, Tamagawa 2-chome
 Ota-ku Tokyo(JP)

Inventor: Ohno, Norio SHOWA DENKO K.K.
 Seikagakukenkyusho 24-25, Tamagawa 2-chome
 Ota-ku Tokyo(JP)



Inventor: Seki, Yumi SHOWA DENKO K.K.
 Seikagakukenkyusho 24-25, Tamagawa 2-chome
 Ota-ku Tokyo(JP)


Representative: Strehl, Schübel-Hopf, Schulz
 Widemayerstrasse 17 Postfach 22 03 45
 D-8000 München 22(DE)

Lysin derivative and proteinase inhibitor.

A lysine derivative having the general formula:
 A-Y-Lys- B (L-form) (A)


wherein A represents






wherein X and X' independently represent hydrogen, halogen, alkyl, cycloalkyl, alkoxy, aryloxy, dialkylamino, alkylcarbonyl amino, arylcarbonyl amino, and n_1 is an integer of 3 to 6, n_2 is an integer of 1 to 3, and n_3 is an integer of 0 to 3;

Y represents SO_2 or CO;
 -Lys- represents



B represents NR^1R^2 , NZ , W, or tetrahydroquinolyl, wherein R^1 and R^2 independently represents hydrogen provided that both R^1 and R^2 cannot be hydrogen at the same time; alkyl substituted with carboxyl, alkoxycarbonyl, phenyl, hydroxyphenyl, or benzoyl; cycloalkyl which may be substituted with arylcarbonyl; cycloalkyl-alkyl which may be substituted with carboxyl, arylcarbonyl, or aralkyloxycarbonyl; phenyl which may be substituted with halogen, nitro, cyano, trifluoromethyl, alkyl, alkoxy, alkoxycarbonyl, alkoxy-

carbonylalkyl, phenylalkyl which may be further substituted with dialkylamino, alkylcarbonyl, phenylalkenyl which may be further substituted with dialkylamino, phenoxy, phenylcarbonyl which may be further substituted with an amino, dialkylamino, alkoxycarbonyl, or nitro group, pyridymethyl, phenyl hydroxyalkyl, alkylsulfonyl, or alkoxycarbonyl alkylcarbonyl, coumaryl which may be substituted with alkyl; quinolyl; adamantyl; norbornyl; or tetrahydronaphthyl; and



W is hydrogen; hydroxyl; carboxyl; aminocarbonyl; alkyl; alkoxy carbonyl; phenyl; phenylalkyl which may be substituted with dialkylamino; or phenylcarbonyl which may be substituted with alkoxycarbonyl; or tetrahydroquinolyl; and

$$m_1 + m_2 = 3 \text{ or } 4$$

or the pharmaceutically acceptable salt thereof.

This lysine derivative is effective as a proteinase inhibitor.

LYSIN DERIVATIVE AND PROTEINASE INHIBITOR

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a novel lysine derivative or the pharmaceutically acceptable salt thereof. More specifically, it relates to an L-lysine derivative having a proteinase inhibition activity (e.g., plasmin inhibition activity) or the pharmaceutical acceptable salt thereof and a proteinase inhibitor containing the same as an essential component.

2. Description of the Related Art

It is well-known in the art that various proteinases are present in human organisms. Examples of such proteinases are plasmin, thrombin, trypsin, kallikrein, and urokinase. As is known, when these proteinases are abnormally activated, various diseases are caused. For example, when abnormally activated plasmin is present in a relatively large amount in the blood, hemorrhagic disorder or inflammatory disorder are caused. For this reason, a substance capable of exhibiting a proteinase inhibition activity is useful as a clinical remedy or medicine.

It has been reported in, for example, J. Biol. Chem. 208, 85 (1954) and J. Biochem., 57, 450 (1965) that certain derivatives of lysine and arginine have an inhibition activity against plasmin, which is a proteinase specific to fibrin and fibrinogen in blood. However, the plasmin inhibition activity of the reported substances is low and, therefore, practical use of those substances as a medicine is not acceptable in the art.


SUMMARY OF THE INVENTION

An object of the present invention is to provide a novel compound having an effective proteinase inhibition activity suitable for use as a proteinase inhibitor such as plasmin inhibitor.

Other objects and advantages of the present inven-

In accordance with the present invention, there is provided a lysine derivative having the general formula:

wherein A represents



$$\begin{array}{c} (\text{CH}_2)_4\text{-NH}_2 \\ | \\ \text{-Lys- represents -NH-CH-CO-} \end{array}$$

B represents NR^1R^2 , NZW , or tetrahydroquinolyl wherein R^1 and R^2 independently represents hydrogen
 5 provided that both R^1 and R^2 cannot be hydrogen at the same time; alkyl preferably having 1 to 6 carbon atoms substituted with carboxyl, alkoxycarbonyl preferably having 2 to 6 carbon atoms, phenyl, hydroxyphenyl, or benzoyl; cycloalkyl preferably having 5 to 8 carbon
 10 atoms, which may be substituted with arylcarbonyl preferably having a C_6 to C_{10} aryl group; cycloalkyl-alkyl preferably having 6 to 11 carbon atoms, which may be substituted with carboxyl, arylcarbonyl preferably having a C_6 to C_{10} aryl group, or aralkyloxycarbonyl
 15 preferably having a C_7 to C_{11} aralkyl group; phenyl which may be substituted with halogen, nitro, cyano, trifluoromethyl, alkyl preferably having 1 to 5 carbon atoms, alkoxy preferably having 1 to 5 carbon atoms, alkoxycarbonyl preferably having 2 to 10 carbon atoms,
 20 alkoxycarbonylalkyl preferably having 3 to 10 carbon atoms, phenylalkyl preferably having 7 to 10 carbon atoms which may be further substituted with dialkylamino preferably having a C_1 to C_3 alkyl group, alkylcarbonyl preferably having a C_1 to C_{10} alkyl group, phenylalkenyl
 25 preferably having 8 to 10 carbon atoms which may be further substituted with dialkylamino preferably having a C_1 to C_3 alkyl group, phenoxy, phenylcarbonyl which may be further substituted with amino, dialkylamino preferably having a C_1 to C_3 alkyl group, alkoxycarbonyl
 30 preferably having 2 to 6 carbon atoms, or nitro, pyridylmethyl, phenyl hydroxyalkyl preferably having a C_1 to C_3 alkyl group, alkylsulfonyl preferably having a C_1 to C_{20} alkyl group, or alkoxycarbonyl alkylamino-carbonyl preferably having 4 to 6 carbon atoms; coumaryl
 35 which may be substituted with alkyl preferably having 1 to 5 carbon atoms; quinolyl; adamantyl; norbornyl; or tetrahydronaphthyl; and

Z is $-(\text{CH}_2)_{\overline{m}_1}-\overset{|}{\text{CH}}(\text{CH}_2)_{\overline{m}_2}-$ or $-(\text{CH}_2)_{\overline{m}_1}-\overset{|}{\text{N}}-(\text{CH}_2)_{\overline{m}_2}$;
 W is hydrogen; hydroxyl; carboxyl; amino-

carbonyl; alkyl preferably having 1 to 10 carbon atoms;
 alkoxy carbonyl preferably having 2 to 10 carbon atoms;
 5 phenyl; phenylalkyl preferably having 7 to 12 carbon
 atoms which may be substituted with dialkylamino
 preferably having a C_1 to C_3 alkyl group; or phenyl-
 carbonyl which may be substituted with alkoxy carbonyl
 preferably having 7 to 11 carbon atoms; and
 10 $m_1 + m_2 = 3$ or 4;
 or the pharmaceutically acceptable salt
 thereof.

Examples of the pharmaceutically acceptable salts
 are inorganic acid salts such as hydrochloride,
 15 hydrobromide, sulfate, nitrate, and phosphate and
 organic acid salts such as oxalate, succinate, malate,
 citrate, lactate, benzene sulfonate, toluene sulfonate,
 and methane sulfonate.

In accordance with the present invention, there
 20 is also provided a proteinase inhibitor containing as
 an essential component the above-mentioned L-lysine
 derivatives or the pharmaceutically acceptable salts
 thereof.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

25 Typical examples of the L-lysine derivatives
 according to the present invention are summarized in
 Table I, wherein (D) indicated under the carbon atom
 of the compound Nos. 12, 15, and 22 denotes that the
 carbon atom is in the D-form and Lys, Phe, and Pro in
 30 the formula of the compounds represent L-lysine,
 phenylalanine, and proline, respectively. In the
 physical properties shown in Table I, NMR represents a
 nuclear magnetic resonance spectrum indicated by δ (i.e.,
 delta) (ppm) representing the chemical shifts. The
 35 determination was carried out by using as a solvent
 CDCl_3 (i.e., heavy chloroform), $(\text{CD}_3)_2\text{SO}$ (i.e.,
 d^6 -dimethylsulfoxide), or CD_3OD (i.e., heavy

methanol) alone or in any mixture thereof and by using as an internal standard TMS (i.e., tetramethylsilane). In the parenthesis after the δ number, the number of the hydrogen atom and the symbols s, d, t, q, m, and broad thereafter means singlet, doublet, triplet, quartet, multiplet, and broad absorbance, respectively. The absorbance based on the solvent is deleted from the Table.

IR represents an infrared absorption spectrum in which a potassium bromide tablet is used in the determination unless otherwise noted. When a solution is used in the determination, the kind of the solvent is listed in parenthesis. The number listed in the Table represents a wave number in units of cm^{-1} and only the main absorption peaks are listed in the Table.

MS represents a mass spectrum, and the results are shown as M/e (i.e., the mass of the cation fragment divided by the charge) of the main peaks.

Table I (List of Compounds of Present Invention)

Compound No.	Compound	Physical Properties
1		NMR: CDCl_3 , TMS δ 1.5 (10H, m) 2.3 (3H, s) 2.4 (1H, s) 2.5 - 4.5 (11H, m) 7.1 - 7.9 (9H, m)
2		MS: m/e 413, 395, 368, 356, 326, 312, 255, 241, 238
3		IR: 1690, 1600, 1160, 1310

Table I (List of Compounds of Present Invention) (Continued)






Compound No.	Compound	Physical Properties
4		MS: 541, 399, 318, 267, 240, 207, 176, 160, 148, 128 IR: 3400, 1680, 1580, 1150
5		MS: 356, 312, 283, 255, 238, 226, 183, 171, 155 IR: 1640, 1340, 1160
6		IR: 1680, 1600, 1320, 1160
7		IR: 1720, 1700, 1660, 1615, 1575, 1520, 1420, 1380, 1320, 1160
8		MS: 518, 500, 464, 455, 374, 359, 345, 342 IR: 1720, 1670, 1660, 1600, 1540, 1450, 1365, 1320, 1240, 1180, 1160

Table I (List of Compounds of Present Invention) (Continued)




Compound No.	Compound	MS:	Physical Properties
9		MS: m/e 284, 339 NMR: $CDCl_3$, TMS δ 7.58 - 6.96 (8H, m) 2.0 - 3.0 (13H, m) 3.3 - 3.6 (1H, t) 0.8 - 1.8 (10H, broad)	
10		IR: 1695, 1600, 1310, 1160	
11		IR: 1700, 1630, 1540, 1450, 1320, 1240, 1160, 1130 NMR: $CDCl_3$, TMS δ 0.70 - 2.35 (12H, m) 2.50 - 3.00 (2H, m) 4.0 - 5.20 (4H, m) 7.40 - 9.0 (10H, m)	

Table I (List of Compounds of Present Invention) (Continued)

Compound No.	Compound	Physical Properties
12		MS: M/e 475, 303, 256, 120, 84 NMR: CDCl_3 , TMS δ 1.08 - 1.80 (9H, m) 2.42 (3H, s) 2.60 - 3.20 (4H, m) 4.15 (2H, q) 7.05 - 7.98 (9H, m)
13		IR: 1660, 1600, 1310, 1160
14		MS: M/e 441, 426, 398, 396, 368, 269, 255
15		MS: M/e 477, 432, 378, 350, 333, 305, 303, 283, 255, 231, 179, 171, 155, 127, 91 IR: 1730, 1650, 1325, 1160

Table I (List of Compounds of Present Invention) (Continued)

Compound No.	Compound	Physical Properties
16		IR: 1650, 1600, 1320, 1160 MS: 354, 255, 227, 155, 84 IR: 1635, 1320, 1160
17		MS: 354, 255, 227, 155, 84 IR: 1635, 1320, 1160
18		MS: 255, 237, 155, 127, 84 NMR: CD3OD, TMS δ 1.08 - 1.95 (6H, broad) 2.12 (3H, s) 2.80 - 3.15 (2H, broad) 7.05 - 7.90 (13H, broad)
19		MS: 358, 247, 231, 200, 183, 168, 157, 127, 84 IR: 3400, 1710, 1640, 1160

Table I (List of Compounds of Present Invention) (Continued)





Compound No.	Compound	Physical Properties
20		IR (CHCl ₃) 1690, 1600, 1320, 1160
21		MS: M/e 457, 339, 385, 285, 283, 255, 238, 202, 174, 84 NMR: Free CDCl ₃ , TMS δ 1.2 - 2.0 (10H, broad) 2.06 - 3.18 (11H, m) 3.8 - 4.2 (2H, broad) 6.80 - 7.88 (9H, m)
22		MS: M/e 461, 416, 388, 290, 255, 171, 127, 105, 84 IR: 1740, 1660, 1160
23		IR: 1700, 1600, 1320, 1160

Table I (List of Compounds of Present Invention) (Continued)





Compound No.	Compound	Physical Properties
24		MS: M/e 479, 407, 291, 271, 191, 127, 84 NMR: CDCl ₃ -CD ₃ OD, TMS δ 1.35 - 1.90 (10H, broad) 2.35 - 3.00 (2H, broad) 3.05 - 4.40 (4H, m) 6.80 - 8.80 (12H, m)
25		MS: M/e 375, 248, 203, 155, 93, 84 NMR: CDCl ₃ , TMS δ 1.20 - 2.0 (6H, broad) 2.20 (3H, s) 2.50 - 2.95 (1H, broad) 3.47 (6H, broad) 6.90 - 8.0 (9H, m)
26		MS: M/e 278, 255, 246, 227, 156, 139, 123, 118, 84 NMR: CDCl ₃ , TMS δ 1.20 - 1.95 (6H, broad) 2.30 (3H, s) 2.45 - 3.02 (2H, broad) 3.25 - 4.20 (2H, broad) 7.10 - 7.90 (8H, broad)
27		IR: 1721, 1620, 1600, 1300, 1140

Table J (List of Compounds of Present Invention) (Continued)






Compound No.	Compound	Physical Properties
28		MS: M/e 389, 255, 238, 217, 155, 107, 84 IR: 3300, 3250, 1665, 1315, 1140
29		MS: M/e 400, 382, 343, 317, 278, 255, 246, 238, 227
30		IR (CHCl3) 1700, 1640, 1300, 1160
31		MS: M/e 467, 312, 293, 255, 185, 155, 127, 84 IR: 1680, 1220, 1155
32		MS: M/e 425, 427, 333, 271, 255, 209, 161, 84 NMR: CDCl3, TMS δ 0.90 - 2.0 (6H, broad) 2.10 - 2.95 (5H, m) 4.40 - 5.05 (2H, broad) 6.90 - 8.10 (8H, m)

Table I (List of Compounds of Present Invention) (Continued)









Compound No.	Compound	Physical Properties
33		MS: M/e 274, 255, 209, 165, 127, 120, 110, 84 NMR: CDCl ₃ , TMS δ 1.08 - 1.88 (6H, broad) 2.26 (3H, s) 2.58 (2H, m) 3.76 (3H, s) 3.12 - 4.56 (8H, m) 6.56 - 7.84 (7H, m)
34		MS: M/e 435, 263, 231, 153, 84 NMR: CDCl ₃ , TMS δ 1.08 - 1.88 (6H, broad) 2.26 (3H, s) 2.58 (2H, m) 3.76 (3H, s) 3.12 - 4.56 (8H, m) 6.56 - 7.84 (7H, m)
35		MS: M/e 443, 271, 255, 161, 155, 127, 84 IR: 1680, 1590, 1480, 1160, 820
36		MS: M/e 443, 271, 255, 161, 155, 127, 84 IR: 1680, 1590, 1480, 1160, 820 NMR: CDCl ₃ , TMS δ 1.10 - 1.82 (6H, broad) 2.21 (3H, s) 2.50 - 2.75 (2H, m) 3.90 - 4.05 (2H, m) 6.90 - 7.85 (13H, m)

Table I (List of Compounds of Present Invention) (Continued)

Compound No.	Compound	Physical Properties
37		IR: (CHCl ₃) 1640, 1600, 1340, 1160
38		MS: M/e 255, 238, 226 IR: 1745, 1640, 1160
39		NMR: Free CDCl ₃ , TMS δ 1.10 - 1.80 (6H, broad) 2.40 (3H, s) 2.72 (3H, s) 2.60 - 2.85 (2H, broad) 6.90 - 7.85 (9H, m)
40		MS: M/e 475, 430, 320, 303, 255 193, 155, 148, 84 IR: 1710, 1640, 1160

0183271

Table I (List of Compounds of Present Invention) (Continued)





Compound No.	Compound	Physical Properties
41		IR (CHCl ₃): 1640, 1600, 1342, 1160
42		MS: M/e 267, 255, 185, 158, 155, 127, 84 IR: 1685, 1520, 1320, 1160
43		MS: M/e 544, 490, 360, 285, 276, 260, 203, 197, 174, 105, 84 NMR: CDCl ₃ , TMS δ 1.12 - 2.08 (10H, broad) 2.16 - 2.56 (2H, broad) 2.60 - 4.04 (7H, broad) 6.80 - 8.60 (14H, m)
44		MS: M/e 358, 331, 247, 231, 200, 167, 127, 110, 84 IR: 3550, 1740, 1160, 750

TABLE 1. LIST OF COMPOUNDS OF PRESENT INVENTION (Continued)






Compound No.	Compound	Physical Properties
45		IR: 1640, 1600, 1330, 1160
46		MS: M/e 403, 358, 356, 283, 171, 163, 155 IR: 1720, 1630, 1430, 1280, 1160
47		MS: M/e 472, 407, 381, 362, 255, 155, 84 NMR: CDCl3, TMS δ 1.30 - 2.05 (8H, m) 2.15 (3H, s) 2.30 - 3.65 (15H, m) 6.20 - 6.90 (9H, m)
48		MS: M/e 536, 463, 361, 334, 316, 285, 251, 234, 174, 170, 84 IR: Free 1630, 1320, 1140
49		IR (CHCl3) 1710, 1640, 1335, 1160

Table I (List of Compounds of Present Invention) (Continued)






Compound No.	Compound	Physical Properties
50		MS: 444, 326, 312, 272, 255, 189, 161, 145, 132, 119, 84 IR: 1640, 1590, 1310, 1140
51		MS: 317, 250, 235, 197, 171, 127, 80 IR: 1690, 1640, 1590, 1140
52		MS: 422, 292, 285, 209, 192, 174, 129, 84 IR: 1635, 1335, 1170, 1145
53		IR (CHCl3) 1724, 1644, 1340, 1160
54		MS: 358, 331, 247, 231, 200, 168, 127, 91, 84 IR: 3400, 1720, 1660, 1150

Table I (List of Compounds of Present Invention) (Continued)

Compound No.	Compound	Physical Properties
55		MS: M/e 466, 293, 282, 255, 211, 184, 127, 106, 84 IR: 1670, 1600, 1155
56		MS: M/e 521, 449, 401, 319, 285, 235, 219, 174, 155, 84 IR: 1630, 1150
57		IR: 1722, 1645, 1600, 1335, 1160
58.		MS: M/e 335, 321, 239, 212, 171, 156, 139, 124, 120, 92, 91
59		MS: M/e 544, 374, 235, 197, 188, 155, 91, 80 IR: 1690, 1585, 1150

Table I (List of Compounds of Present Invention) (Continued)





Compound No.	Compound	Physical Properties	
60		MS: M/e 533, 413, 331, 285, 247, 231, 174, 167, 84	IR: 1680, 1620, 1160
61		IR: 1650, 1600, 1330, 1160	
62		MS: M/e 345, 237, 231, 168, 80	IR: 1720, 1150
63		MS: M/e 527, 482, 456, 440, 428, 386, 340, 298, 256, 198, 174, 126, 93, 84	NMR: (CD3O)2SO, TMS δ 1.0 - 1.80 (10H, broad) 2.14 (3H, s) 2.20 - 3.88 (8H, broad) 7.80 - 8.20 (9H, m)

Table I (List of Compounds of Present Invention) (Continued)






Compound No.	Compound	Physical Properties
64		MS: M/e 446, 354, 285, 240, 208 180, 174, 152, 101, 84
65		IR: 1670, 1630, 1598, 1320, 1160
66		MS: M/e 396, 318, 223, 207, 197, 192, 176, 160, 128 NMR: CDCl ₃ , TMS δ 1.0 - 1.88 (6H, m) 2.60 (2H, broad) 3.00 - 4.10 (3H, m) 6.96 - 9.04 (16H, m)
67		MS: M/e 291, 247, 231, 200, 168, 84 IR: 1690, 1650, 1590, 1310, 1150
68		MS: M/e 350, 246, 171, 155, 120, 91, 80 IR: 1680, 1650, 1590, 1525, 1270, 1155

Table I (List of Compounds of Present Invention) (Continued)




Compound No.	Compound	Physical Properties
69		MS: M/e 340, 231, 154 NMR: CDCl_3 , TMS δ 1.20 - 1.92 (6H, broad) 2.36 (3H, s) 2.70 (3H, d) 3.04 - 3.84 (3H, broad) 3.96 (1H, m) 7.16 - 8.84 (12H, m)
70		MS: M/e 314, 291, 247, 232, 216, 200, 197, 183, 168, 80 IR: 1690, 1650, 1585, 1310, 1150
71		MS: M/e 291, 274, 207, 197, 160, 128, 80 IR: 1680, 1640, 1585, 1150

TABLE I. LIST OF COMPOUNDS OF PRESENT INVENTION (Continued)




Compound No.	Compound	Physical Properties	
72		MS: M/e 367, 292, 263, 201, 183, 155, 106, 91, 83	NMR: CDCl ₃ , TMS δ 1.15 - 1.88 (6H, m) 2.28 (3H, s) 2.48 - 3.24 (2H, m) 3.90 (3H, m) 6.88 - 8.68 (13H, m)
73		MS: M/e 503, 347, 264, 238, 223, 222, 171, 155, 139, 91	NMR: CDCl ₃ , TMS δ 1.16 - 1.84 (6H, broad) 1.84 - 2.44 (3H, broad) 2.50 - 3.10 (2H, m) 2.96 (6H, s) 6.60 - 6.95 (2H, m) 7.0 - 7.88 (12H, m)
74		IR: 3400, 1685, 1640, 1590, 1150	NMR: CDCl ₃ , TMS δ 1.10 - 1.84 (6H, broad) 2.60 - 2.84 (2H, broad) 3.88 (3H, s) 6.80 - 8.70 (15H, m)

Table I (List of Compounds of Present Invention) (Continued)

Compound No.	Compound	MS:	NMR:	Physical Properties
75		MS: M/e 493, 475, 421, 291, 285, 274, 191, 174, 127	NMR: CDCl ₃ , TMS δ 0.68 - 2.04 (10H, m) 2.06 - 2.80 (3H, m) 3.0 - 4.32 (6H, m) 6.72 - 8.60 (12H, m)	
76		MS: M/e 444, 374, 346, 302, 292, 235, 220, 209, 204, 188, 156, 106, 83	NMR: CDCl ₃ -CD ₃ OD, TMS δ 1.12 - 1.88 (6H, m) 2.12 - 2.92 (8H, m) 3.84 (3H, broad) 6.72 - 8.40 (14H, m)	
77		MS: M/e 323, 255, 246, 238, 171, 156, 139, 124, 108, 92, 84		
78		MS: M/e 291, 211, 197, 196, 183, 164, 131, 84	IR: 1680, 1650, 1590, 1150	

Table I (List of Compounds of Present Invention) (Continued)

Compound No.	Compound	Physical Properties	
79		MS: M/e 255, 238, 226, 173, 156, 91, 84	IR: 3320, 2940, 2900, 2840, 1670, 1630, 1440, 1320, 1155
80		MS: M/e 493, 336, 309, 285, 225, 209, 175, 146, 118, 84	NMR: CDCl ₃ , TMS δ 1.20 - 2.16 (10H, m) 2.24 - 3.08 (6H, m) 3.40 - 3.80 (1H, broad) 3.96 - 4.36 (1H, broad) 6.40 - 8.20 (10H, m)
81		MS: M/e 298, 287, 240, 208, 180, 152, 84, 64	IR: 1675, 1635, 1585, 1440, 1320, 1285, 1175, 1150
82		MS: M/e 304, 195, 127, 110, 99, 91, 83	NMR: CDCl ₃ , TMS δ 1.24 - 1.88 (6H, m) 2.28 (3H, s) 2.40 - 3.0 (6H, broad) 3.88 (1H, m) 6.98 - 7.82 (15H, m)

Table I (List of Compounds of Present Invention) (Continued)






Compound No.	Compound	Physical Properties
88		MS: M/e 398, 358, 304, 200, 195, 168 IR: 1690, 1640, 1150
89		MS: M/e 288, 230, 198, 197, 165, 120, 80 IR: 1690, 1640, 1150
90		MS: M/e 457, 358, 331, 247, 231, 209, 167, 127, 84 IR: 3400, 1640, 1150
91		NMR: CDCl ₃ , TMS δ 1.16 - 2.0 (14H, m) 2.0 - 2.96 (7H, m) 3.40 - 3.72 (1H, broad) 3.80 - 4.36 (4H, m) 6.88 - 7.84 (8H, m) MS: M/e 497, 425, 295, 285, 195, 174, 131, 84 IR: 1670, 1640, 1580, 1520, 1320, 1280, 1175, 1145, 197, 120
92		MS: M/e 446, 417, 413, 389, 341, 306, 287, 240, 223, 208, 197, 120 IR: 1670, 1640, 1580, 1520, 1320, 1280, 1175, 1145, 197, 120

Table I (List of Compounds of Present Invention) (Continued)




Compound No.	Compound	Physical Properties
93		MS: m/e 358, 331, 314, 247, 231, 215, 202, 200, 183, 168, 93, 83 NMR: $(CD_3)_2SO$, TMS δ 0.96 - 1.84 (6H, m) 2.10 - 3.08 (3H, m) 6.68 - 8.64 (12H, m)
94		MS: m/e 535, 517, 463, 360, 333, 285, 233, 174 NMR: $CDCl_3$, TMS δ 0.90 - 1.80 (10H, broad) 2.40 - 3.0 (2H, m) 3.0 - 4.40 (6H, m) 6.60 - 7.92 (14H, m)
95		MS: m/e 525, 507, 453, 323, 285, 202, 174, 159 NMR: $CDCl_3-(CD_3)_2SO$, TMS δ 0.84 - 2.04 (20H, m) 2.25 - 2.80 (4H, m) 3.24 - 4.36 (4H, m) 6.88 - 8.64 (9H, m)

Table I (List of Compounds of Present Invention) (Continued)




Compound No.	Compound	MS:	NMR:	Physical Properties
96		M/e 382, 306, 291, 239, 223, 208, 197, 192, 183, 160, 149, 136, 80	NMR: CD ₃ OD, TMS δ 0.84 - 1.88 (20H, m) 2.12 - 2.44 (1H, m) 2.64 - 3.10 (2H, m) 3.76 - 4.10 (1H, m) 7.06 - 8.28 (13H, m)	
97		MS: M/e 398, 366, 349, 266, 247, 240, 200, 168, 148, 139	NMR: CDCl ₃ , TMS δ 1.08 - 1.88 (6H, broad) 2.59 (2H, broad) 3.06 (6H, s) 3.24 - 3.68 (3H, broad) 4.04 (1H, m) 6.52 - 8.12 (14H, m) 8.56 (1H, s)	
98		MS: M/e 446, 287, 240, 208, 119, 93, 84, 80		

Table I (List of Compounds of Present Invention) (Continued)





Compound No.	Compound	Physical Properties
99.		MS: M/e 389, 288, 270, 215 201, 179, 106, 84
100		MS: M/e 498, 323, 304, 285, 175, 132, 84 NMR: CDCl ₃ , TMS δ 0.88 - 2.00 (13H, m) 2.02 - 2.88 (10H, m) 3.16 - 3.58 (4H, m) 3.68 - 3.96 (1H, m) 4.24 (1H, t) 5.84 (1H, s) 6.48 (1H, q) 6.80 - 7.48 (8H, m)
101		IR: 3440, 1680, 1600 NMR (free) CD ₃ OD, TMS δ 1.10 - 2.00 (6H, m) 2.55 (3H, s) 2.90 - 3.50 (2H, m) 3.30 (4H, s) 7.00 - 8.40 (8H, m)
102.		IR: 3440, 1650, 1150

Table I (List of Compounds of Present Invention) (Continued)




Compound No.	Compound	Physical Properties
103		NMR: CD_3OD , TMS δ 0.8 - 2.0 (17H, m) 2.2 - 2.3 (1H, broad) 2.5 - 2.6 (2H, m) 2.7 - 2.8 (2H, m) 2.85 - 3.2 (4H, broad) 4.4 - 4.12 (1H, m) 7.04 - 7.92 (5H, m)
104		NMR: CH_3OD , TMS δ 0.8 - 2.0 (24H, m) 2.20 (2H, s) 2.44 (2H, m) 2.62 (2H, m) 2.92 - 3.0 (2H, m) 3.04 - 3.12 (2H, m) 4.04 - 4.28 (5H, m) 4.30 - 4.48 (1H, m) 7.20 - 7.60 (4H, m)
105		IR: 1640, 1600

Table I (List of Compounds of Present Invention) (Continued)

Compound No.	Compound	Physical Properties
106		IR: 532, 503, 487, 328, 265, 220, 191, 128, 84
107		MS: M/e 354, 336, 261, 230, 222, 221, 203, 128, 93, 84
108		IR: 3600 - 2400, 1680, 1600, 1520, 1490, 1445, 1300 NMR: CD ₃ OD, TMS δ 1.40 - 1.70 (6H, broad, s) 3.16 (2H, s) 7.0 - 8.08 (9H, m)
109		MS: M/e 443, 250, 191, 177, 177, 136, 128, 120, 83

Table I (List of Compounds of Present Invention) (Continued)




Compound No.	Compound	Physical Properties
110	 <chem>CCOC(=O)c1ccc(NC(CC1)CCNC)cc1</chem>	IR: 1640, 1590, 1700
111	 <chem>CCOC(=O)c1ccccc1C(=O)N(CC2CCCCC2)CCNC</chem>	IR: 1640, 1590, 1700, 1690
112	 <chem>CCOC(=O)N1CCCC1CCc2ccccc2</chem>	IR: 1640, 1600

Table I (List of Compounds of Present Invention) (Continued)

Compound No.	Compound	Physical Properties
113		IR: 1640, 1600, 1720
114		IR: 1640, 1600, 1710
115		IR: 1640, 1600, 1720
116		IR: 1640, 1600, 1480, 1340
117		IR: 1740, 1640, 1600

Table I (List of Compounds of Present Invention) (Continued)




Compound No.	Compound	Physical Properties
118		IR: 1640, 1600, 1490, 1720
119		MS: M/e 483, 465, 346, 237, 246 NMR: CDCl ₃ , TMS δ 1.33 (6H, t) 1.2 - 2.2 (6H, broad) 2.3 (3H, s) 2.6 - 3.2 (3H, broad) 4.35 (4H, q) 4.6 - 5.4 (4H, broad) 7.1 - 7.9 (4H, m) 8.3 (1H, s) 8.5 (2H, s)
120		NMR: CDCl ₃ , TMS δ 1.4 - 2.0 (6H, broad) 2.38 (6H, s) 2.2 - 3.0 (3H, broad) 4.7 - 5.2 (4H, broad) 7.0 - 8.0 (8H, m)

Table I (List of Compounds of Present Invention) (Continued)





Compound No.	Compound	Physical Properties
121		MS: M/e 382, 364, 346, 263, 246, 136, 119
122		MS: M/e 421, 246, 219, 176 119, 84 NMR: CDCl_3 , TMS δ 0.95 - 1.95 (11H, broad) 2.38 (3H, s) 2.20 - 3.10 (7H, m) 3.85 - 5.20 (2H, m) 7.00 - 7.80 (9H, m)
123		NMR: CDCl_3 , TMS δ 1.30 - 2.20 (6H, broad) 2.50 - 2.70 (2H, m) 3.20 - 3.30 (1H, broad) 4.10 - 5.10 (3H, m) 6.50 - 7.98 (14H, m) IR: 3400, 1660, 1600
124		NMR: CDCl_3 , TMS δ 1.20 - 2.10 (6H, broad) 2.36 - 2.72 (2H, m) 4.96 - 5.24 (1H, m) 6.81 - 8.40 (10H, m)

Table I (List of Compounds of Present Invention) (Continued)





Compound No.	Compound	Physical Properties
125		IR: 1640, 1600, 1510, 1450, 1480 - 1490
126		IR: 1640, 1630, 1600, 1510, 1490, 1450
127		MS: M/e 485, 357, 351, 268, 240, 219, 134, 84 NMR: CD_3CO_2 , TMS δ 0.80 - 2.00 (15H, m), 2.20 - 3.20 (11H, m), 2.88 (6H, s), 3.30 - 4.50 (5H, m), 6.70 - 7.40 (4H, m)
128		NMR: $CDCl_3$, TMS δ 0.85 - 2.05 (15H, m), 2.20 - 2.75 (11H, m), 3.30 - 3.80 (4H, m), 4.20 (1H, m), 7.00 - 7.50 (5H, m)

Table I (List of Compounds of Present Invention) (Continued)






Compound No.	Compound	Physical Properties
129		MS: 326, 223, 188 IR: 3375, 2900, 1670, 1600, 1440, 1250, 1205
130		IR: 1680 - 1690, 1640, 1430
131		MS: 470, 441, 412, 313, 267, 241, 204, 187, 157, 105, 84 IR: 3270, 2920, 1680, 1660, 1640, 1630, 1550
132		MS: 470, 441, 412, 313, 267, 241, 204, 187, 157, 105, 84 IR: 3275, 2925, 1670, 1660, 1630, 1550
133		IR: 1640, 1510, 1450

Table I (List of Compounds of Present Invention) (Continued)





Compound No.	Compound	Physical Properties
134		MS: M/e 484, 469, 467, 455, 426, 327, 267, 218, 110, 105, 84
135		MS: M/e 514, 358, 267, 191, 120, 84
136		IR: 1740, 1640, 1510, 1450
137		NMR: CD ₃ CO, TMS δ 0.84 - 2.02 (22H, m) 2.12 - 2.36 (2H, m) 2.48 (2H, d) 2.64 (2H, t) 4.60 - 4.92 (1H, m) 7.08 - 8.0 (5H, m) 2.8 - 3.76 is not known because of overlapping with the solvent.

Table I (List of Compounds of Present Invention) (Continued)






Compound No.	Compound	Physical Properties
138		IR: 1640, 1510, 1450
139		IR: 1640, 1510, 1450
140		IR: 1720 - 1730, 1640, 1600, 1490
141		IR: 1690, 1680, 1640, 1600, 1490 NMR: CD ₃ OD, TMS δ 0.8 - 2.0 (15H, m) 2.1 - 2.4 (1H, m) 2.65 (2H, d) 2.80 (2H, t) 4.35 - 4.55 (1H, m) 7.75 - 7.85 (9H, m)
142		MS: M/e 308, 279, 267, 140, 128, 84 IR: 3350, 1630

Table I (List of Compounds of Present Invention) (Continued)




Compound No.	Compound	Physical Properties
143		IR: 1690, 1640, 1510, 1450
144		IR: 3300, 2810, 1610, 1540, 1390 NMR: $\text{CD}_3\text{OD, TMS}$ δ 0.8 - 2.0 (15H, m) 2.08 - 2.4 (1H, m) 2.50 (2H, d) 2.64 (2H, t) 4.12 - 4.48 (1H, m) 5.72 (1H, s) 7.16 - 7.92 (9H, m)
145		MS: M/e 402, 267, 251, 238, 135, 120, 110 IR: 3280, 2920, 1680, 1660, 1600, 1540, 1280, 860

Table I (List of Compounds of Present Invention) (Continued)






Compound No.	Compound	Physical Properties
146		MS: 462, 267, 195, 140, 128, 84 IR: 3360, 1650, 1510
147	 (cis rich)	IR: 1690, 1640, 1600, 1490
148		IR: 1690, 1640, 1600, 1510, 1490, 1450
149		IR: 1690, 1640, 1600, 1490
150		MS: 433, 415, 375, 329, 286, 243, 106, 84 IR: 2845, 1670, 1650, 1610, 1540, 1390, 1010

Table I (List of Compounds of Present Invention) (Continued)





Compound No.	Compound	Physical Properties
151	 $\text{H}_2\text{N}(\text{CH}_2)_5\text{CO-Lys-NHCH}_2$	MS: M/e 458, 442, 429, 400, 371, 327, 210, 131, 105, 84 NMR: CDCl_3 , TMS δ 0.70 - 3.50 (28H, m) 4.40 (2H, broad) 7.34 - 7.60 (3H, m) 7.84 - 8.00 (2H, d)
152	 $\text{H}_2\text{N}(\text{CH}_2)_5\text{CO-Lys-NH}$	IR: 3250, 2900, 1642, 1600, 1540, 1310, 1262, 1185, 858 NMR: $\text{CD}_3\text{OO-CDCl}_3$, TMS δ 0.70 - 2.78 (14H, m) 2.58 (3H, s) 3.05 - 3.60 (5H, m) 4.50 (2H, broad) 7.50 - 8.00 (5H, m)
153	 $\text{H}_2\text{N}(\text{CH}_2)_5\text{CO-Lys-NH}$	MS: M/e 265, 237 IR: 3350, 1690, 1625, 1550, 1400, 1325, 1240
154	 $\text{H}_2\text{N}(\text{CH}_2)_5\text{CO-Lys-NH}$	MS: M/e 362, 307, 195 IR: 3350, 2900, 2830, 1630, 1585, 1520, 1305, 1275

Table I (List of Compounds of Present Invention) (Continued)








Compound No.	Compound	MS:	IR:	Physical Properties
155		M/e 241, 183, 292	3320, 1640, 1620, 1550, 1400, 1300	
156		M/e 306, 197	3200, 2980, 2870, 2800, 1620, 1580, 1510, 1430, 1395, 1300, 1265, 1240	
157		M/e 306, 246, 197	3350, 1620, 1560, 1480, 1400, 1320	
158		NMR: CD ₃ OD, TMS δ 1.24 - 1.62 (6H, m) 2.48 - 2.70 (2H, m) 3.82 (2H, s) 4.36 - 4.52 (1H, m) 7.22 - 7.96 (13H, m)		

Table I (List of Compounds of Present Invention) (Continued)

Compound No.	Compound	IR	Physical Properties
159		IR: 1690, 1650, 1600, 1500	
160		MS: M/e 407, 378, 349, 336 271	

The lysine derivatives according to the present invention can be synthesized by various combinations of the so-called peptide synthesis methods. The synthesis routes can be typically divided into the following two routes.

The terms "N terminal" and "C terminal" of lysine used herein mean as follows.



A) The N terminal group of lysine is first introduced into the starting commercially available N⁶-benzyloxycarbonyl-L-lysine

(i.e., H-Lys-OH wherein-CBZ=-COOCH₂-φ) and the C terminal group of lysine is then introduced thereinto, followed by removing the protective group CBZ.

B) The C terminal group of lysine is first introduced into the starting commercially available N²-t-butyloxycarbonyl-N⁶-

benzyloxycarbonyl-L-lysine (i.e., BOC-Lys-OH wherein BOC=-COO-C(CH₃)₃), the BOC group is then selectively removed therefrom in a known manner, and the N terminal group of lysine is further introduced, followed by removing the CBZ group.

Furthermore, in the practice of the introduction of the N terminal group and the C terminal group, the following methods can be utilized:

(a) The introduction of the N terminal group can be introduced by using aromatic sulfonyl chlorides (i.e., ArSO₂Cl) or aromatic carbonyl chlorides (i.e., ArCOCl)

(b) The introduction of the C terminal group can be introduced by the following known methods

(i) Mixed acid anhydride method [Ann, Chem., 572, 190 (1951)]

(ii) Acid chloride method Biochemistry.

4, 2219 (1960)]

(iii) Phosphazo method [Chem. Ber., 93, 2387 (1960)]

(iv) N,N'-dicyclohexylcarbodiimide method [J. Am. Chem. Soc., 77, 1067 (1955)]


(v) Active ester method using, for example, N-hydroxysuccinimide [J. Am. Chem. Soc., 85, 3039 (1963)]

It should be noted, however, that the desired synthesis methods must be selected by appropriately combining the above-mentioned methods. Typical routes for synthesizing the lysine derivatives are exemplified as follows. In the following routes, the amine


portion represented by $\text{HN} \begin{matrix} \nearrow \text{R}^1 \\ \searrow \text{R}^2 \end{matrix}$ may be substituted with


$\text{HN} \begin{matrix} \text{---} \end{matrix} \text{Z-W.}$

Route (1)



N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide





(5)

The synthesis of the compound (2) from the compound (1) can be carried out by using the so-called Schotten-Baumann reaction. That is, the starting compound (1) is dissolved or suspended in a suitable solvent system (e.g., ethyl ether-water, toluene-water, 1,4-dioxane-water, acetone-water and a suitable base (e.g., NaOH, NaHCO₃, K₂CO₃) is added in an amount of, for example, 1 to 5 equivalent, preferably 2 to 3 equivalent, to the compound (1). To the resultant mixture, an aromatic sulfonyl or an aromatic carbonyl chloride (i.e., ArSO₂Cl or ArCOCl) is added alone or as a solution in an organic solvent used in the reaction medium. The addition may be carried out all at once or in several portions. The reaction is generally carried out at a temperature of -10°C to 30°C, preferably 5°C to 10°C for 1 to 50 hours, preferably 5 to 20 hours. The compound (2) can be recovered from the reaction mixture in any conventional manner.

The synthesis of the compound (3) from the compound (2) can be carried out by the method (b)-(v) set forth above.

The compound (4) can be prepared from the compound (3) as follows. That is, the compound (3) is dissolved in a suitable organic solvent (e.g., ethers, hydrocarbons, halogenated hydrocarbons, N,N'-dialkylformamides, nitriles) and a 1 to 3 equivalent amount of


HN $\begin{array}{l} \nearrow \text{R}^1 \\ \searrow \text{R}^2 \end{array}$ is added thereto. The reaction is generally

carried out at a temperature of -10°C to 30°C, preferably

0°C to 20°C for 1 to 50 hours, preferably 5 to 20 hours. After completing the reaction, the compound (4) can be recovered in any conventional manner.

The synthesis of the compound (5) from the compound (4) can be carried out by the so-called HBr/AcOH method [see J. Am. Chem. Soc., 81, 5688 (1959)] or the so-called H₂-Pd catalytic hydrogenation method [see Chem. Ber., 65, 1192 (1932)] .

Route ②



The compound (1) is dissolved in a suitable dried solvent (e.g., ethers, halogenated hydrocarbons) and, while the reaction temperature is maintained at -10°C to 30°C, preferably 0°C to 5°C, a 1.0 to 5.0 equivalent, preferably 1.0 to 1.5 equivalent, amount of phosphorus pentachloride is added all at once or over a period of 10 minutes to 1 hour, preferably 10 to 20 minutes, with stirring. After the addition, the reaction mixture is further stirred for 30 minutes to 1 hour while maintaining the above-mentioned temperature range.

Thereafter, the reaction mixture is allowed to stand with stirring at room temperature for 10 minutes to 2 hours, preferably for 10 minutes to 1 hour. The solvents and the other volatile substances are distilled
5 off in vacuo at a temperature of 10°C to 70°C, preferably 30°C to 50°C. Thus, the compound (2) can be obtained.


Since the compound (2) is unstable, the synthesis of the compound (3) from the compound (2) is preferably carried out immediately. That is, the compound (2) is
10 dissolved in a suitable dried solvent (e.g., ethers, halogenated hydrocarbons, hydrocarbons)

and a 1 to 3 equivalent amount of $\text{HN} \begin{array}{l} \nearrow \text{R}^1 \\ \searrow \text{R}^2 \end{array}$ is added

15 thereto. In this case, tertiary organic amines such as triethylamine may be used. The reaction is generally carried out at a temperature of 0°C to 50°C, preferably 10°C to 20°C for 1 to 50 hours, preferably 5 to 20 hours. After completing the reaction, the compound (3) can be
20 recovered in any conventional post-treatment method.

The synthesis of the compound (4) from the compound (3) can be carried out in the same manner as in the above-mentioned route (1).


Route (3)



In the route (3), the starting commercially available compound (1) is first dissolved in a suitable dried solvent (e.g., ethyl acetate, 1,4-dioxane, tetrahydrofuran) and a 1 to 5 equivalent amount,

preferably a 1 to 2 equivalent amount, of a suitable
tertiarily organic amine (e.g., triethylamine) is added
thereto in an amount of 1 to 5 equivalent, preferably 1
to 2 equivalent, to the compound (1). The resultant
5 solution is cooled to a temperature of -20°C to 10°C,
preferably -15°C to 0°C. Then, a 1 to 3 equivalent,
preferably 1 to 1.5 equivalent amount of ethyl
chlorocarbonate (or phenyl chlorocarbonate) is added to
the cooled solution and the reaction is carried out for
10 5 minutes to one hour with stirring. After completing
the reaction, a solution containing the compound (2) can
be obtained in any conventional post-treatment method.

To the solution obtained above, a 1 to 3 equivalent
of



is added at a temperature of 15°C to 0°C. After
the addition, the mixture is allowed to react at the
same temperature for 10 minutes to 5 hours, and at a
20 temperature of 5°C to 30°C, preferably 10°C to 20°C for
10 to 50 hours. After completing the reaction, the
compound (3) can be recovered in any conventional
post-treatment method.

The synthesis of the compound (4) from the compound
25 (3) can be carried out by a known method as disclosed
in, for example, Proc. Natl. Acad. Sci., 58, 1806 (1967).


The synthesis of the compound (5) from the compound
(4) can be carried out either by using the so-called
Schotten-Baumann reaction set forth in the above-
30 mentioned route (1) or by using a suitable organic
solvent (e.g., ethers, N,N-dialkylformamide, N,N-
dialkylacetamide, halogenated hydrocarbons) in
combination with a suitable tertiary organic base
(e.g., trialkylamines, dialkylanilines, pyridine).

35 The synthesis of the compound (6) from the compound
(1) can be carried out in the same manner as in the above-
mentioned route (1).


Furthermore, in the case where the amino group is contained as a terminal group of the N terminal of lysine, the lysine derivative according to the present invention can be similarly prepared in the following routes (4) and (5).

The L-lysine derivatives obtained above can be converted to the pharmaceutically acceptable salts thereof in any conventional manner.





Route (4)



wherein Q is a residue of the group A defined above from which a group NH_2 is removed.



Route (5)



The L-lysine derivatives or the pharmaceutically acceptable salts thereof according to the present invention, which are an effective component of the proteinase inhibitor of the present invention

5 have remarkable inhibition activities against proteinases such as plasmin, kallikrein, trypsin, and urokinase as shown in the below-mentioned test results shown in Tables IV and V. It has not been

10 exhibiting no substantial inhibition activities against thrombin exhibit the above-mentioned unique enzyme inhibition pattern. Furthermore, ϵ -aminocaproic acid, tranexamic acid and other compounds, which are

15 heretofore widely used as plasmin inhibitors, have an activity capable of selectively inhibiting the fibrin dissolving action of plasmin and, therefore, are used as useful hemostatics. This pharmacological action is believed to be effected by the fact that these

20 compounds are bonded to the so-called lysine binding sites (i.e., LBS) of plasminogen and plasmin, whereby the binding of fibrin to the plasminogen and plasmin is prevented as reported in, for example, Chem. Rev., 81, 431 (1981), Biochem. J., 163, 389 (1977), and Eur. J. Biochem., 84, 573 (1978). These compounds have no

25 substantial activities to prevent the decomposition of synthetic substrates (e.g., S-2251 available from Kabi Co., Ltd.) and fibrinogen caused by plasmin. This means that, although various substrates (e.g., fibrinogen), other than fibrin, are present in the

30 human organisms for plasmin the above-mentioned compounds are not effective for preventing the decomposition of these substrates.

Contrary to the above, the proteinase inhibitors according to the present invention have

35 remarkable inhibition activities against the decomposition of the synthetic substrates and fibrinogen as well as the decomposition of fibrin

by plasmin and, therefore, are novel antiplasmins suitable for use as a hemostatic agent against hemorrhagic disorders and inflammatory disorders.

5 On the other hand, known compound Nos. 4, 5, 7, and 8 listed in Table II having a structure similar to those of the present compounds has only a very low inhibition activity against the action of plasmin as shown in Table III. It is clear from
10 the comparison of the results in Tables III and IV that the inhibition activities of the present compounds shown in Table IV are far superior to that of said compounds.

15 Furthermore, as shown in Table V, some L-lysine derivatives according to the present invention have inhibition activities against urokinase, which is a plasminogen activating enzyme. This means that the present L-lysine derivatives provide favorable results as a hemostatic agent. In addition, some
20 L-lysine derivatives according to the present invention exhibit inhibition activities against kallikrein and trypsin. This means that these inhibition activities can provide, together with the antiplasmin activity, a strong anti-inflammatory
25 agent.

When the L-lysine derivatives or the pharmaceutically acceptable salts thereof are used as a medicine, there are no critical limitations to the administration methods. The present proteinase inhibitor can be
30 formulated by any conventional method. For example, the present proteinase inhibitor may be applied in any conventional manner including intravenous injection, intramuscular injection, subcutaneous injection, intravenous drip, and oral administration.
35 Although there are no critical limitations to the administration dosage, the suitable dosage is 100 to 1000 mg/day/person.

EXAMPLES

The present invention will now be further illustrated by, but is by no means limited to, the following Examples illustrating the synthesis of the present compounds as well as the pharmacological test data for the evaluation thereof.

Example 1

Synthesis of N^2 -(p-toluenesulfonyl)-L-lysine-4-benzylpiperidinamide (i.e., Compound No. 1)

A 5 g amount of N^6 -benzyloxycarbonyl lysine (I) was dissolved in 100 ml of 1,4-dioxane, 150 ml of water, and 4.92 g of K_2CO_3 . A solution of 3.74 g of p-toluenesulfonyl chloride in 15 ml of 1,4-dioxane was dropwise added to the solution for 1.5 hours. The resultant mixture was allowed to stand with stirring for one night, while maintaining the temperature at 15°C. Thereafter, the 1,4-dioxane and water were distilled off in vacuo.

Water was charged to the residue and the resultant mixture was then washed with ethyl ether. The resultant two phases were separated and the aqueous phase was extracted with ethyl acetate after acidifying the aqueous phase by the addition of hydrochloric acid.

The extract was treated in a conventional manner, followed by crystallizing from ethanol-n-hexane to obtain 5.0 g of N^2 -(p-toluenesulfonyl)- N^6 -benzyloxycarbonyl-L-lysine (II).

A 2.2 g amount of the compound (II) and 580 mg of N-hydroxysuccinimide were dissolved in 20 ml of 1,4-dioxane. Then, 1.05 g of N,N'-dicyclohexylcarbodiimide (DCC) was added and the mixture was allowed to stand for one night at a temperature of 5°C to 10°C. Thereafter, the mixture was treated in a conventional manner to obtain 2.6 g of N^2 -(p-toluenesulfonyl)- N^6 -(benzyloxycarbonyl)-L-lysine N-hydroxysuccinimide ester (III).

A 1.06 g amount of the compound (III) was dissolved in 15 ml of 1,4-dioxane and 350 mg of 4-benzylpiperidine

was then added. The mixture was allowed to react at a temperature of 10°C for 10 hours, while stirring. The reaction mixture was then treated in a conventional manner to obtain 820 mg of N²-(p-toluene sulfonyl)-N⁶-benzyloxycarbonyl-L-lysine 4-benzylpiperidinamide (IV).

A 1.5 ml amount of a 30% hydrogen bromide in acetic acid solution was added to 820 mg of the compound (IV). After the mixture was agitated at room temperature for 20 minutes, diethyl ether was added to precipitate the desired N²-(p-toluenesulfonyl)-L-lysine 4-benzylpiperidinamide hydrobromide (V). The ether was removed by decantation. After the ether washing was repeated several times, an aqueous sodium bicarbonate solution was added to the washed precipitate so that the resultant mixture became alkaline. The alkaline mixture was extracted with chloroform, followed by a conventional treatment. Thus, 650 mg of the desired compound (V) was obtained.

Example 2

Synthesis of N²-(dibenzofuran-2-sulfonyl)-L-lysine-3-benzoylanilide (i.e., Compound No. 70)

A 980 mg amount of N²-(dibenzofuran-2-sulfonyl)-N⁶-(benzyloxycarbonyl)-L-lysine (I) prepared in the same manner as in Example 1 was dissolved in 5 ml of 1,4-dioxane and 5 ml of tetrahydrofuran. Then, 800 mg of phosphorus pentachloride was dropwise added to the solution under ice cooling for 10 minutes with stirring. The stirring was continued for a further 10 minutes.

The resultant mixture was stirred at room temperature for 30 minutes and the mixture was then distilled in vacuo at a temperature of 45°C in a water bath to remove 1,4-dioxane and other elements. Then, 10 ml of 1,4-dioxane was charged to the residue and 380 mg of 3-benzoylaniline was added thereto. The mixture was allowed to stand at room temperature for one night. The resultant mixture was then treated in a conventional manner to obtain 890 mg of N²-(dibenzofuran-2-sulfonyl)-

N^6 -(benzyloxycarbonyl)-L-lysine 3-benzoylanilide (II).

A 890 mg amount of the compound (II) was treated with 2.0 ml of a 30% hydrogen bromide in acetic acid solution to obtain 130 mg of the desired N^2 -(dibenzo-
5 furan-2-sulfonyl)-L-lysine 3-benzoylanilide.

Example 3

Synthesis of N^2 -(coumarin-6-sulfonyl)-L-lysine-4-benzylpiperidinamide (i.e., Compound No. 80)

A 1.0 g amount of N^2 -(t-butyloxycarbonyl)- N^6 -(benzyloxycarbonyl)-L-lysine and 320 mg of triethylamine
10 were dissolved in 10 ml of tetrahydrofuran. While the solution was cooled in an ice-salt bath, 330 mg of ethyl chlorocarbonate was added with stirring. About 20 minutes later 460 mg of 4-benzylpiperidine was added.
15 After stirring for 2 hours, the mixture was allowed to stand at room temperature for one night. The mixture was then treated in a conventional manner to obtain 1.1 g of N^2 -(t-butyloxycarbonyl)- N^6 -(benzyloxycarbonyl)-L-lysine 4-benzylpiperidinamide (I).

20 A 1.1 g amount of the compound (I) was dissolved in 3.5 ml of 6N-hydrogen chloride-1,4-dioxane and the mixture was stirred at room temperature for about 5 minutes. A 3.5 ml amount of 1,4-dioxane was further added and the mixture was allowed to stand at room
25 temperature for one hour. Then, 20 ml of ethyl ether was added to settle oily N^6 -benzyloxycarbonyl-L-lysine 4-benzylpiperidinamide hydrochloride (II). The ethyl ether was separated by decantation. After this procedure was repeated several times, an aqueous sodium bicarbonate
30 solution was added and the compound (II) was then extracted with chloroform. The extract was dried over sodium sulfate and the chloroform was distilled off in vacuo.

35 A 500 mg amount of the compound (II) was dissolved in a solution of 630 mg of potassium carbonate dissolved in 6 ml of water and 20 ml of 1,4-dioxane and 280 mg of coumarin-6-sulfonyl chloride was added thereto. The

mixture was treated in the same manner as in Example 1 to obtain 350 mg of N^2 -(coumarin-6-sulfonyl)- N^6 -(benzyloxycarbonyl)-L-lysine 4-benzylpiperidine (III).

5 A 260 mg amount of the compound (III) was treated with 0.5 ml of a 30% hydrobromic acid in acetic acid solution to obtain 50 mg of the desired N^2 -(coumarin-6-sulfonyl)-L-lysine 4-benzylpiperidin amide.

Example 4

10 Synthesis of N^2 -(p-toluene sulfonyl)-L-lysine p-nitroanilide hydrochloride (i.e., Compound No. 3)

A 1.4 g amount of p-nitroaniline was dissolved in 20 ml of pyridine and, while cooling in an ice-salt bath, 0.71 g of phosphorus trichloride was added thereto, followed by stirring for 15 minutes.

15 After the temperature of the mixture had returned to room temperature, 4.3 g of N^2 -(p-toluenesulfonyl)- N^6 -(benzyloxycarbonyl)-L-lysine was added thereto and the resultant mixture was stirred at a temperature of 60°C for 3 hours. The resultant mixture was then treated in
20 a conventional manner to obtain 3.5 g of N^2 -(p-toluene-sulfonyl)- N^6 -(benzyloxycarbonyl)-L-lysine p-nitroanilide (I).

The benzyloxycarbonyl group at N^6 position was removed from 1.2 g of the compound (I) in the same
25 manner as in Example 1 to obtain 380 mg of N^2 -(p-toluenesulfonyl)-L-lysine p-nitroanilide hydrochloride.

Example 5

Synthesis of N^2 -(p-toluenesulfonyl)-L-lysine
4-cyanoanilide (i.e., Compound No. 26)

30 A 1.0 g amount of N^2 -(p-toluenesulfonyl)- N^6 -(benzyloxycarbonyl)-L-lysine and 270 mg of p-cyanoaniline were added to 15 ml of toluene and, while stirring, 200 mg of phosphorus trichloride was added at room temperature over 5 minutes. The resultant reaction
35 mixture was allowed to react under reflux in an oil bath at a temperature of 120°C for 3.5 hours while stirring.

The resultant reaction mixture was then treated in

a conventional manner to obtain 980 mg of N^2 -(p-toluene-sulfonyl)- N^6 -(benzyloxycarbonyl)-L-lysine 4-cyanoanilide (I). The benzyloxycarbonyl group at N^6 position of the compound (I) was removed from the compound (I) in the same manner as in Example 1 to obtain 510 mg of the desired N^2 -(p-toluenesulfonyl)-L-lysine 4-cyanoanilide.

Example 6

Synthesis of N^2 -(p-toluenesulfonyl)-L-lysine 4-nitrobenzylamide acetate (i.e., Compound No. 16)

A 4.3 g amount of N^2 -(p-toluenesulfonyl)- N^6 -(benzyloxycarbonyl)-L-lysine and 1.55 g of p-nitrobenzylamine were dissolved in 5 ml of N,N-dimethylformamide and 5 ml of acetonitrile and, while cooling in an ice-salt bath, 2.5 g of N,N'-dicyclohexylcarbodiimide was added thereto. The resultant mixture was allowed to react for one hour and was then allowed to stand at room temperature for one night. The reaction mixture was treated in a conventional manner to obtain 2.9 g of N^2 -(p-toluene sulfonyl)- N^6 -(benzyloxycarbonyl)-L-lysine 4-nitrobenzylamide (I).

The benzyloxycarbonyl group at N^6 position was removed from 430 mg of the compound (I) in the same manner as in Example 1 to obtain 340 mg of the desired N^2 -(p-toluenesulfonyl)-L-lysine 4-nitrobenzylamide acetate.

Example 7

Synthesis of N^2 -(trans-4-aminomethylcyclohexyl-carbonyl)-L-lysine 4-isopropyloxycarbonylanilide (i.e., Compound No. 115)

A 0.54 g amount of 4-isopropyloxycarbonylaniline was dissolved in 20 ml of N,N-dimethylformamide and the mixture was stirred under ice cooling. On the other hand, 1.14 g of N^2 -(t-butyloxycarbonyl)- N^6 -(benzyloxycarbonyl)-L-lysine (I) was dissolved in 40 ml of dry tetrahydrofuran and, while ice cooling, 300 mg of triethylamine was added. Then, while ice-salt cooling, 330 mg of ethyl chlorocarbonate was added, followed by

stirring for 15 minutes. This solution was added to the above-prepared solution and the mixture was allowed to stand at a temperature of 4°C for one night. The reaction mixture was then treated in a conventional manner to obtain 1.2 g of N²-(t-butyloxycarbonyl)-N⁶-(benzyloxycarbonyl)-L-lysine 4-isopropylloxycarbonyl-anilide (II).

A 1.2 ml amount of a 6N-hydrogen chloride in dioxane solution was added to 360 mg of the compound (II) while ice cooling. Ten minutes later, 1.2 ml of dioxane was added thereto and the mixture was stirred at room temperature for 30 minutes. Twenty minutes later, 50 ml of N,N-dimethylformamide was added to the resultant reaction solution while-ice cooling, followed by adding 0.9 ml of triethylamine.

On the other hand, 0.2 g of trans-4-benzyloxy-carbonyl aminomethylcyclohexanecarboxylic acid was dissolved in 5 ml of chloroform and 0.18 ml of thionyl chloride was added under room temperature. After the mixture was allowed to stand for 5 hours, the mixture was added to the above-prepared reaction solution and the mixture was allowed to stand at room temperature for 12 hours. The resultant reaction mixture was treated in a conventional manner to obtain 150 mg of N²-(trans-4-benzyloxycarbonylaminomethylcyclohexylcarbonyl)-L-lysine 4-isopropylloxycarbonyl anilide (III).

A 84 mg amount of the compound (III) was suspended in ethanol and 10 mg of palladium black was added thereto. Thus, the reaction was carried out at room temperature for 9 hours with stirring under a hydrogen gas flow. As a result, 33 mg of the desired N²-(trans-4-aminomethylcyclohexylcarbonyl)-L-lysine 4-isopropyl-oxycarbonylanilide (IV) was obtained from a ether-petroleum ether solvent.

Example 8

Synthesis of N²-(trans-4-aminomethylcyclohexyl-carbonyl)-L-lysine 4-(ethoxycarbonylmethyl)

carbamoyl anilide (i.e., Compound No. 109)

A 744 mg amount of trans-4-aminomethylcyclohexane-carboxylic acid and 574 mg of triethylamine were dissolved in 16 ml of tetrahydrofuran and, while cooling
5 in an ice-salt bath, 282 mg of ethyl chlorocarbonate was added thereto with stirring. After stirring for 20 minutes, 1.0 g of N⁶-benzyloxycarbonyl-L-lysine 4-(ethoxycarbonylmethyl) carbamoyl anilide hydrochloride (I) prepared in a conventional manner was added. The
10 mixture was stirred for about 2 hours under cooling and was then allowed to stand at room temperature for one night.

Example 9

Synthesis of N²-(p-toluoyl)-L-lysine

15 3,5-diethoxycarbonylanilide (i.e., Compound No. 119)

A 5 g amount of N⁶-benzyloxycarbonyl-L-lysine (I) was dissolved in 100 ml of 1,4-dioxane, 150 ml of water, and 4.92 g of potassium carbonate. While maintaining
20 the solution at a temperature of 10°C, a solution of 4.17 g of p-toluenecarbonyl chloride dissolved in 15 ml of 1,4-dioxane was dropwise added thereto with stirring for 2 hours. After the resultant mixture was further maintained at a temperature of 10°C for 3 hours,
25 the mixture was allowed to stand for one night at 4°C. The 1,4-dioxane and water were distilled off and, after adding water thereto, the mixture was washed with ethyl ether. The resultant two phases were separated and, after acidifying the aqueous phase by adding hydro-
30 chloric acid, the aqueous phase was extracted with ethyl acetate. The extract was treated in a conventional manner. The product was crystallized from acetone to obtain 4.3 g of N²-(p-toluoyl)-N⁶-benzyloxycarbonyl-L-lysine (II).

35 A 796 mg amount of the compound (II) and 474 mg of 3,5-diethoxycarbonylaniline were added to 15 ml of toluene and 200 mg of phosphorus trichloride was added

thereto at room temperature for 5 minutes with stirring. The reaction mixture was refluxed upon heating with stirring for 2.5 hours. The reaction mixture was treated in a conventional manner to obtain 910 mg of

5 N^2 -(p-toluoyl)- N^6 -(benzyloxycarbonyl)-L-lysine 3,5-diethoxycarbonylanilide (III).

A 1.5 ml amount of a 30% hydrogen bromide in acetic acid solution was added to 800 mg of the compound (III) and the mixture was stirred at room temperature for 15 minutes. Then, diethyl ether was added to precipitate the desired N^2 -(p-toluoyl)-L-lysine 3,5-diethoxycarbonylanilide (IV) in the form of a hydrobromide salt. After the ether was removed by decantation and the ether washing was repeated several

10 times, an aqueous sodium bicarbonate solution was added thereto and the resultant alkaline mixture was extracted with chloroform. The extract was treated in a conventional manner to obtain 230 mg of the desired compound (IV).

15

20 Example 10

Synthesis of N^2 -(p-toluoyl)-L-lysine 4-methyl-7-coumarinyl amide (i.e., Compound No. 120)

A 774 mg amount of N^2 -(p-toluoyl)- N^6 -(benzyloxycarbonyl)-L-lysine (I) and 343 mg of 7-amino-4-methyl coumarin were added to 15 ml of toluene and 200 mg of phosphorus trichloride was added thereto at room temperature for 5 minutes with stirring. The reaction mixture was refluxed upon heating for 3 hours with stirring. The resultant mixture was treated in a conventional

25 manner to obtain 765 mg of N^2 -(p-toluoyl)- N^6 -(benzyloxycarbonyl)-L-lysine 4-methyl-7-coumarinyl amide (II).

30

A 720 mg amount of the compound (II) was treated with 1.5 ml of a 30% hydrogen bromide in acetic acid solution to obtain 210 mg of the desired N^2 -(p-toluoyl)-L-lysine 4-methyl-7-coumarinylamide.

35

Example 11

Synthesis of N^2 -(1-naphthalenecarbonyl)-L-lysine

3,4-dichloroanilide (i.e., Compound No. 124)

A 500 mg amount of N^2 -(1-naphthalene carbonyl)- N^6 -(benzyloxycarbonyl)-L-lysine (I) was dissolved in 10 ml of 1,4-dioxane and, while cooling in an ice bath, 280 mg of phosphorus pentachloride was added and the mixture was stirred for about 10 minutes.

After the temperature of the mixture had returned to room temperature, the mixture was stirred for 30 minutes and the solvent and the other evaporating components were distilled off in a water bath at a temperature of 40°C to 50°C.

Thereafter, 10 ml of 1,4-dioxane was again added to the resultant residue and 370 mg of 3,4-dichloroaniline was added at room temperature with stirring. The reaction was completed in one hour. The reaction mixture was then treated in a conventional manner to obtain 380 mg of N^2 -(1-naphthalenecarbonyl)- N^6 -(benzyloxycarbonyl)-L-lysine 3,4-dichloroanilide (II) in the form of a powder.

A 200 mg amount of the compound (II) was treated with 1.0 ml of a 30% hydrogen bromide in acetic acid solution to obtain 120 mg of the desired N^2 -(1-naphthalenecarbonyl)-L-lysine 3,4-dichloroanilide.

Example 12

Synthesis of N^2 -benzoyl-L-lysine 4-benzoylanilide (i.e., Compound No. 123)

A 1.83 g amount of N^2 -(t-butyloxycarbonyl)- N^6 -(benzyloxycarbonyl)-L-lysine and 590 mg of triethylamine were dissolved in 15 ml of tetrahydrofuran. While cooling in an ice-salt bath, 530 mg of ethyl chloro-carbonate was added thereto with stirring and, about 20 minutes later, 950 mg of 4-benzoylaniline was added.

After stirring for 2 hours, the mixture was allowed to stand at room temperature for one night. The mixture was then treated in a conventional manner to obtain 2.4 g of N^2 -(t-butyloxycarbonyl)- N^6 -(benzyloxycarbonyl)-L-lysine 4-benzoylanilide (I).

A 600 mg amount of the compound (I) was dissolved in a 6N-hydrogen chloride in 2 ml of 1,4-dioxane solution and the mixture was stirred at room temperature for about 5 minutes. Then, 2 ml of 1,4-dioxane was added thereto and the mixture was allowed to stand at room temperature for one hour. Thereafter, 10 ml of ethyl ether was added, N⁶-(benzyloxycarbonyl)-L-lysine 4-benzoylanilide (hydrochloride) (II) was precipitated. The ethyl ether was separated by decantation. After this procedure was repeated several times, the product was recovered by filtration. The compound (II) was dissolved in 6 ml of N,N-dimethylformamide and 340 mg triethylamine was added. The mixture was stirred at room temperature for 5 minutes and 150 mg of benzoyl chloride was added thereto. The mixture was then stirred at room temperature for 5 hours. The resultant mixture was treated in a conventional manner to obtain 400 mg of N²-benzoyl-N⁶-(benzyloxycarbonyl)-L-lysine 4-benzoylanilide (III).

A 400 mg amount of the compound (III) was treated with 1.0 ml of a 30% hydrogen bromide in acetic acid solution to obtain 180 mg of the desired N²-benzoyl-L-lysine 4-benzoylanilide.

Example 13

Synthesis of N²-(p-toluoyl)-L-lysine 4-benzylpiperidin amide (i.e., Compound No. 122)

A 800 mg amount of N²-(p-toluoyl)-N⁶-(benzyloxycarbonyl)-L-lysine (I) and 250 mg of N-hydroxy succinimide were dissolved in 15 ml of 1,4-dioxane and, after adding 440 mg of N,N'-dicyclohexyl carbodiimide (DCC) thereto, the mixture was allowed to stand at a temperature of 5°C to 10°C for one night. The insoluble matter was filtered off. To the filtrate, 350 mg of 4-benzylpiperidine was added and the mixture was allowed to react at a temperature of 10°C for 10 hours with stirring. The resultant reaction mixture was then treated in a conventional manner to obtain 910 mg of

N^2 -(p-toluoyl)- N^6 -(benzyloxycarbonyl)-L-lysine
4-benzylpiperidinamide (II).

A 910 mg amount of the compound (II) was treated
with 2.0 ml of a 30% hydrogen bromide in acetic acid
5 solution to obtain 400 mg of the desired N^2 -(p-toluoyl)-
L-lysine 4-benzylpiperidin amide.

Example 14

Synthesis of N^2 -(6-amino-1-oxo-hexyl)-L-lysine
4-benzylanilide (i.e., Compound No. 112)

10 A 2.45 g amount of N^1 -(t-butyloxycarbonyl)- N^6 -
(benzyloxycarbonyl)-L-lysine (I) was dissolved in 10 ml
of tetrahydrofuran and 800 mg of triethylamine was then
added thereto. While cooling in an ice bath, 800 mg of
ethyl chlorocarbonate was added and the mixture was
15 stirred for about 20 minutes. The mixture was suction
filtered by using, as a receiver, 790 mg of 4-benzyl-
aniline dissolved in a small amount of tetrahydrofuran.
After allowing the stand for one night, the resultant
mixture was extracted with ethyl acetate. The extract
20 was treated in a conventional manner to obtain 3.04 g of
 N^2 -(t-butyloxycarbonyl)- N^6 -(benzyloxycarbonyl)-L-lysine
4-benzylanilide (II).

A 2 g amount of 6-benzyloxycarbonyl aminocaproic
acid was dissolved in 30 ml of chloroform and, after
25 adding 1.1 g of thionyl chloride, the mixture was
stirred for 30 minutes. The resultant mixture was
distilled in vacuo. Then, n-hexane was added to the
residue and 2.2 g of 6-benzyloxycarbonyl aminocaproyl
chloride (III) was recovered therefrom by filtration.

30 A 10 ml amount of a 6N-hydrogen chloride in dioxane
solution was added to 3.04 g of the compound (II) and
the mixture was stirred at room temperature for one
hour. After adding 10 ml of 1,4-dioxane, the mixture
was allowed to stand at room temperature. One hour
35 later, diethyl ether was added to the mixture. The
decantation was repeated several times and 30 ml of
N,N-dimethylformamide was added. To the mixture, 2.3 g

of triethylamine and 2.2 g of the compound (III) were added and the mixture was warmed at a temperature of 40°C. After allowing to stand for one night, the triethylamine hydrochloride was filtered off and the solvent was distilled off. The residue was then extracted with chloroform. The extract was then treated in a conventional manner to obtain 1.8 g of N²-(6-benzyloxycarbonyl amino-1-oxo-hexyl)-N⁶-(benzyloxy-carbonyl)-L-lysine 4-benzylanilide (IV).

- 10 A 500 mg amount of the compound (IV) was treated with 1.5 ml of a 30% hydrogen bromide in acetic acid solution to obtain 280 mg of the desired N²-(6-amino-hexylcarbonyl)-L-lysine 4-benzylanilide.

Example 15

- 15 Synthesis of N'-(4-aminobenzenecarbonyl)-L-lysine 4-benzoyl-anilide (i.e., Compound No. 159)

- A 5 g amount of 4-aminobenzoic acid was dissolved in 55 ml of a 2N aqueous sodium hydroxide solution and, while cooling in an ice bath, 6.8 g of benzyloxycarbonyl chloride was added thereto, followed by stirring under ice cooling for 3 hours. The resultant mixture was treated in a conventional manner and to obtain 4.8 g of 4-benzyloxycarbonylaminobenzoic acid (I) by crystallizing from ethyl acetate.

- 25 A 0.5 g amount of N²-(t-butyloxycarbonyl)-N⁶-(benzyloxycarboxyl)-L-lysine 4-benzoylanilide (II) was dissolved in a 6N hydrogen chloride in 1,4-dioxane solution while cooling in an ice bath and 0.4 g of N⁶-(benzyloxycarbonyl)-L-lysine 4-benzoylanilide hydrochloride was obtained therefrom in the same manner as in Example 14. This product was dissolved in 15 ml of N,N-dimethylformamide and, while cooling in an ice bath, 0.27 ml of triethylamine was added thereto. A 0.39 g amount of the compound (I) was dissolved in chloroform and 0.4 ml of thionyl chloride was added thereto at room temperature. After 5 hours, the chloroform and the other evaporating materials were distilled

off. To the residue, 15 ml of N,N-dimethylformamide was added to prepare the solution and this solution was then added to the previously prepared solution.

5 The N,N-dimethylformamide and the other evaporating components were distilled off and the residue was extracted with ethyl acetate. The extract was treated in a conventional manner to obtain 0.51 g of N²-(4-benzyloxycarbonylamino benzenecarbonyl)-N⁶-(benzyloxycarbonyl)-L-lysine 4-benzoylanilide (III).

10 A 83.7 mg amount of the compound (III) was dissolved in 8 ml of water-ethanol and the mixture was subjected to a catalytic reduction. After 14 hours, palladium was filtered off and the filtrate was treated with ethyl ether in a conventional-manner to crystallize 39.3 mg of

15 N²-(4-aminobenzenecarbonyl)-L-lysine 4-benzoylanilide (IV).

Example 16

Synthesis of N²-(trans-4-aminomethylcyclohexyl-carbonyl)-L-lysine 4-styrylanilide (i.e., Compound

20 No. 146)

A 4.35 g amount of N²-(t-butyloxycarbonyl)-N⁶-(benzyloxycarbonyl)-L-lysine and 1.39 g of triethylamine were dissolved in 50 ml of tetrahydrofuran. While cooling in an ice-salt bath, 1.24 g of ethyl chloro-

25 carbonate was added with stirring. After about 20 minutes, 2.23 g of 4-aminostyrene was added. After the mixture was stirred for about 2 hours, the resultant mixture was allowed to stand at room temperature for one night. The mixture was then treated in a conventional

30 manner to obtain 4.7 g of N²-(t-butyloxycarbonyl)-N⁶-(benzyloxycarbonyl)-L-lysine 4-styrylanilide (I).

A 2.0 g amount of the compound (I) was dissolved in 4.8 ml of a 6N-hydrogen chloride in 1,4-dioxane solution and the mixture was stirred at room temperature for

35 about 5 minutes. Furthermore, 4.8 ml of 1,4-dioxane was added thereto and the mixture was allowed to stand at room temperature for one night. Then, 20 ml of ethyl

ether was added, N⁶-(benzyloxycarbonyl)-L-lysine 4-styrylanilide hydrochloride (II) was precipitated. The ethyl ether was removed by decantation. This procedure was repeated several times. The compound (II) was dissolved in 10 ml of N,N-dimethylformamide and 460 mg of triethylamine was added thereto. After the mixture was stirred at room temperature for 5 minutes, 700 mg of trans-4-benzyloxycarbonylaminomethylcyclohexylcarbonyl chloride was added and the mixture was stirred at room temperature for 5 hours. The resultant mixture was treated in a conventional manner to obtain 500 mg of N²-(trans-4-benzyloxycarbonyl cyclohexylcarbonyl)-N⁶-(benzyloxycarbonyl)-L-lysine 4-styrylanilide (III).

A 500 mg amount of the compound (III) was treated with 1.5 ml of a 30% hydrogen bromide in acetic acid solution to obtain 220 mg of the desired N²-(trans-4-aminomethylcyclohexylcarbonyl)-L-lysine 4-styrylanilide.

Example 17

Synthesis of N²-(trans-4-aminomethylcyclohexylcarbonyl)-L-lysine 4-acetylanilide (i.e., Compound No. 145)

To 5 ml of a solution of 718 mg of N²-(t-butyloxycarbonyl)-N⁶-(benzyloxycarbonyl)-L-lysine and 223 mg of tetrahydrofuran dissolved in tetrahydrofuran, 2 ml of a solution of 224 mg of ethyl chlorocarbonate in tetrahydrofuran was added with stirring while cooling in an ice bath. After about 30 minutes, 280 mg of 4-aminoacetophenone was added. After the ice bath was removed, the mixture was stirred at room temperature and was then allowed to stand for one night. Ice water was added to the reaction mixture and the resultant mixture was extracted with ethyl acetate. The extract was then treated in a conventional manner to obtain 592 mg of N²-(t-butyloxycarbonyl)-N⁶-(benzyloxycarbonyl)-L-lysine 4-acetylanilide (I).

Then, 3.0 ml of 6N hydrogen chloride in 1,4-dioxane

solution was added to 448 mg of the compound (I). After the mixture was stirred at room temperature for 2 hours, the mixture was concentrated in vacuo. Furthermore, toluene was added to the residue and the mixture was concentrated in vacuo. Thus, N⁶-(benzyloxycarbonyl)-L-lysine-4-acetylanilide hydrochloride (II) was obtained. To this compound (II), 10 ml of a tetrahydrofuran solution containing the mixed acid anhydride of the previously prepared trans-4-(benzyloxycarbonylamino-methyl) cyclohexanecarboxylic acid (III) with ethyl chlorocarbonate and, further, 112 mg of triethylamine were added. The mixture was stirred at room temperature for 4 hours and ice water was then added thereto. The precipitated crystalline substance was recovered by filtration and was thoroughly washed with water. After drying, 328 mg of N²-(trans-4-benzyloxycarbonylamino-methylcyclohexylcarbonyl)-N⁶-(benzyloxycarbonyl)-L-lysine 4-acetylanilide (IV) was obtained.

A 200 mg amount of the compound (IV), 100 mg of 10% Pd-carbon powder, and 4 ml of cyclohexene were dissolved in 20 ml of ethanol and the resultant solution was vigorously stirred for 2 hours. The 10% Pd-carbon powder was filtered off and the filtrate was concentrated in vacuo. The residue was crystallized from ethyl acetate to obtain 57 mg of the desired N²-(trans-4-aminomethylcyclohexylcarbonyl)-L-lysine 4-acetylanilide.

The inhibition activities of the present compounds and the control compounds are evaluated as follows.

(1) Evaluation of Antiplasmin Activity

(i) Determination of prevention activity for fibrin decomposition

An inhibitor sample is dissolved in a 0.18 M borate-physiological salt buffer solution (pH = 7.4) to make the total volume to 600 μ l. To this buffer solution, 200 μ l of a 0.2% bovine fibrinogen, 100 μ l of a 0.3 casein unit/ml human plasmin solution, and 100 μ l

of a 50 unit/ml bovine thrombin solution, all dissolved in the above-mentioned buffer, are added at a temperature of 37°C in a constant temperature bath. Then, the dissolution time of the fibrin mass formed above is determined. Thus, the concentration I_{50} of the inhibitor sample (i.e., 50% inhibition concentration), at which the dissolution time obtained in the absence of the inhibitor (i.e., about 5 minutes) is extended twice, is determined.

10 (ii) Determination of prevention activity
for S-2251 decomposition

An inhibitor sample is dissolved in a 0.05 M Tris-hydrochloric acid buffer solution (pH = 7.4) to make the total volume to 400 μ l. To this solution, 50 μ l of a 3 mM S-2251 solution is added and the mixture is incubated at a temperature of 37°C for 5 minutes in a constant temperature bath. Then, 50 μ l of a 0.2 casein unit/ml human plasmin is added and the mixture is incubated at a temperature of 37°C for 4 minutes. Thereafter, the reaction is stopped by adding 50 μ l of 50% acetic acid.

The absorbance of p-nitroaniline formed in the reaction mixture is determined at 405 nm. Thus, the concentration I_{50} of the inhibitor sample, at which the absorbance is one half (i.e., 1/2) of that obtained in the absence of the inhibitor, is determined.

(iii) Determination of prevention activity
for fibrinogen

An inhibitor sample is dissolved in a 0.18 M borate-physiological salt buffer solution (pH = 7.4) to make the total volume to 400 μ l. To this solution, 500 μ l of a 0.4% bovine fibrinogen solution and 100 μ l of a 1 casein unit/ml human plasmin solution, all dissolved in the above-mentioned buffer are added at a temperature of 37°C in a constant temperature bath. After the mixture is allowed to stand at a temperature of 37°C for 10 minutes, 3800 μ l of the above-mentioned

buffer containing (3.2 mM of tranexamic acid and 200 μ l of a 50 unit/ml bovine thrombin solution are added to terminate the reaction. The mixture is incubated at a temperature of 37°C for 15 minutes to precipitate the fibrin. The fibrin mass thus precipitated is adhered to or wound around a glass rod and is then washed with water. The amount of the remaining fibrinogen is determined according to a tyrosine coloring method using a phenol reagent (see J. Biol. Chem., 73, 627 (1927) .

From the amount of the remaining fibrinogen thus determined, the amount of decomposed fibrinogen is calculated. Thus, the concentration I_{50} of the inhibitor sample, at which the amount of decomposed fibrinogen is one half (i.e., 1/2) of that obtained in the absence of the inhibitor sample, is determined.

(2) Evaluation of Antithrombin Activity

(i) Determination of inhibition activity against fibrin formation

An inhibitor sample is dissolved in a 0.18 M borate-physiological salt buffer solution (pH = 7.4) to make the total volume to 500 μ l. To this solution, 400 μ l of a 0.2% bovine fibrinogen solution and 100 μ l of a 4 unit/ml bovine thrombin solution are added at a temperature of 37°C in a constant temperature bath. Thus, a coagulation time is determined. The inhibitor concentration I_{50} , at which the coagulation time obtained in the absence of the inhibitor is extended twice, is determined.

(ii) Determination of prevention activity for S-2238 decomposition

An inhibitor sample is dissolved in a 0.05 M Tris-hydrochloric acid buffer solution (pH = 8.3) to make a total volume of 400 μ l. To this solution, 50 μ l of a 0.2 mM S-2238 solution is added and the mixture is incubated at a temperature of 37°C for 5 minutes in a constant temperature bath. Then, 50 μ l of a 0.2 unit/ml bovine thrombin solution is added

thereto and the absorbance, at 405 nm, of the p-nitro-aniline formed per minute is determined at a temperature of 37°C by using the so-called initial velocity method. Thus, the concentration I_{50} of the inhibitor sample at which the absorbance is one half (i.e., 1/2) of that obtained in the absence of the inhibitor sample, is determined.

(3) Evaluation of Antitrypsin Activity

10 Determination of inhibition activity
 against S-2238 decomposition

 An inhibitor sample is dissolved in a 0.05 M Tris-imidazole buffer solution (pH = 8.1) and 125 μ l of a 1 mM S-2238 solution is added to make the total volume to 1.20 ml. The mixture is incubated at a temperature of 37°C for 5 minutes in a constant temperature bath. To this mixture, 0.05 ml of bovine trypsin is added and the absorbance, at 405 nm, of the p-nitroaniline formed per minute is determined at a temperature of 37°C by using the so-called initial velocity method. Thus, the concentration I_{50} of the inhibitor sample, at which the absorbance is one half (i.e., 1/2) of that obtained in the absence of the inhibitor sample, is determined.

(4) Evaluation of Anti-Plasma Kallikrein Activity

25 Determination of prevention activity
 for S-2302 decomposition

 An inhibitor sample is dissolved in a 0.05 M Tris-hydrochloric acid buffer solution (pH = 7.8) to make the total volume to 400 μ l. To this solution, 50 μ l of a 2 mM S-2302 solution is added and the mixture is incubated at a temperature of 37°C for 5 minutes in a constant temperature bath. Then, 50 μ l of a 0.12 unit/ml human plasma kallikrein is added and the mixture is incubated at a temperature of 37°C for 5 minutes. Thereafter, 50 μ l of 50% acetic acid is added to terminate the reaction. The absorbance of the p-nitroaniline formed in the reaction mixture is measured

at 405 nm. Thus, the concentration I_{50} of the inhibitor sample, at which the absorbance is one half (i.e., 1/2) of that obtained in the absence of the inhibitor sample, is determined.

5 (5) Evaluation of Antiurokinase Activity

Determination of prevention activity
 for S-2444 decomposition

 An inhibitor sample is dissolved in a
 0.05 M Tris-hydrochloric acid buffer solution (pH = 8.8)
10 to make the total volume to 400 μ l. To this solution,
 50 μ l of a 1 mM S-2444 solution is added and the mixture
 is incubated at a temperature of 37°C for 5 minutes in a
 constant temperature bath. Then, 50 μ l of a 500 unit/ml
 human urokinase is added and the mixture is incubated at
15 a temperature of 37°C for 5 minutes. Thereafter, 50 μ l
 of 50% acetic acid is added to terminate the reaction.
 The absorbance of the p-nitroaniline formed in the
 reaction mixture is measured at 405 nm. Thus, the
 concentration I_{50} of the inhibitor sample, at which
20 the absorbance is one half (i.e., 1/2) of that obtained
 in the absence of the inhibitor sample, is determined.

 The results are shown in Tables II to V.

Table II (List of Known Compounds)

Compound No.	Compound
1	$\text{H}_2\text{NCH}_2 - \text{C}_6\text{H}_{10} - \text{CO}_2\text{H}$ (t-AMCHA)
2	$\text{H}_2\text{N}(\text{CH}_2)_5\text{CO}_2\text{H}$ (EACA)
3	H-Lys-OH
4	$\text{C}_6\text{H}_5 - \text{SO}_2 - \text{Lys-NH}_2$
5	$\text{CH}_3 - \text{C}_6\text{H}_4 - \text{SO}_2 - \text{Lys-OH}$
6	$\text{CH}_3 - \text{C}_6\text{H}_4 - \text{SO}_2 - \text{Arg-OCH}_3$ (TAME)
7	$\text{H}_2\text{N}(\text{CH}_2)_5\text{CO-Lys-OH}$
8	$\text{C}_6\text{H}_5 - \text{CO-Lys-NH}_2$

Table III (Evaluation Results of Known Compounds)

Compound No.	Plasmin		Thrombin		Trypsin		Plasma Kallikrein		I ₅₀ (μM)
	S-2251	Fibrin	Fibrinogen	S-2238	Fibrinogen	S-2238	S-2302	S-2444	
1	75,000	60	9,500	1,000 ^{*1}	1,000 ^{*1}	1,000 ^{*1}	1,000 ^{*1}	1,000 ^{*1}	
2	180,000	200	-	-	-	-	-	-	
3	50,000	9,000	-	-	-	-	-	-	
4	1,000 ^{*1}	1,000 ^{*1}	-	1,000 ^{*1}	1,000 ^{*1}	150 ^{*1}	1,000 ^{*1}	1,000 ^{*1}	
5	1,400	1,000	-	-	-	-	-	-	
6	3,100	1,000	-	-	-	-	-	-	
7	1,000 ^{*1}	1,000 ^{*2}	-	1,000 ^{*1}	1,000 ^{*1}	200 ^{*1}	1,000 ^{*1}	1,000 ^{*1}	
8	1,000 ^{*1}	1,000 ^{*1}	-	1,000 ^{*1}	1,000 ^{*1}	300 ^{*1}	1,000 ^{*1}	1,000 ^{*1}	

*1: 0% Inhibition

*2: 19% Inhibition

Table IV (Evaluation Results of Present Compounds)

Compound No.	I ₅₀ (M)		
	S-2251	Fibrin	Fibrinogen
3	7.0×10^{-4}	7.8×10^{-4}	9.0×10^{-4}
7	3.5×10^{-4}	3.0×10^{-4}	-
8	2.5×10^{-4}	1.4×10^{-4}	-
10	1.7×10^{-3}	3.1×10^{-4}	-
11	3.9×10^{-4}	7.5×10^{-5}	8.0×10^{-5}
18	6×10^{-4}	3.3×10^{-4}	-
20	2×10^{-3}	$. \times 10^{-3}$	-
21	3×10^{-4}	1.3×10^{-4}	-
22	6.5×10^{-4}	6.1×10^{-4}	-
29	4.8×10^{-4}	3.1×10^{-4}	-
31	7.8×10^{-4}	1.5×10^{-4}	-
32	6×10^{-4}	4.2×10^{-4}	-
33	6.5×10^{-4}	5.4×10^{-4}	-
35	3.7×10^{-4}	$1. \times 10^{-4}$	-
36	1.4×10^{-4}	1.3×10^{-4}	2.0×10^{-4}
37	2.0×10^{-3}	7.3×10^{-4}	-
40	5.9×10^{-4}	4.4×10^{-4}	-
42	2.3×10^{-4}	1.4×10^{-4}	-
48	1.3×10^{-4}	7.4×10^{-5}	-
53	6.5×10^{-4}	4.5×10^{-4}	-
54	2×10^{-4}	1×10^{-4}	-
56	2×10^{-4}	$.5 \times 10^{-5}$	-
59	6.9×10^{-5}	$.1 \times 10^{-5}$	-

Table IV (Continued)

Compound No.	I ₅₀ (M)		
	S-2251	Fibrin	Fibrinogen
60	1.5×10^{-4}	3.4×10^{-5}	-
62	1.6×10^{-4}	2.7×10^{-5}	-
64	3.3×10^{-5}	5.0×10^{-5}	-
65	1.5×10^{-3}	8.5×10^{-4}	-
67	5.2×10^{-5}	5.5×10^{-5}	-
68	4.4×10^{-4}	2.2×10^{-4}	-
69	1.6×10^{-4}	1.2×10^{-4}	-
70	7.3×10^{-5}	3.4×10^{-5}	-
72	2.0×10^{-4}	2.3×10^{-4}	-
73	4.4×10^{-5}	-	-
74	7×10^{-5}	1.0×10^{-4}	-
75	3.7×10^{-5}	7.5×10^{-5}	5.0×10^{-5}
76	4.3×10^{-5}	1.2×10^{-4}	-
77	4.6×10^{-4}	1.6×10^{-4}	-
78	3.8×10^{-5}	1.9×10^{-4}	-
80	4.2×10^{-5}	5.1×10^{-5}	8.0×10^{-5}
82	1.3×10^{-4}	1.0×10^{-4}	-
83	8.8×10^{-5}	1.1×10^{-4}	-
85	4.5×10^{-4}	1.7×10^{-4}	-
89	3.2×10^{-5}	2.9×10^{-5}	-
90	2.7×10^{-4}	2.5×10^{-4}	-
91	2.5×10^{-4}	6.1×10^{-5}	-
93	6.8×10^{-4}	3.5×10^{-4}	-

Table IV (Continued)

Compound No.	I ₅₀ (M)		
	S-2251	Fibrin	Fibrinogen
94	2.0×10^{-4}	3.2×10^{-5}	-
95	1.5×10^{-4}	4×10^{-5}	-
97	3×10^{-4}	5×10^{-4}	-
104	1.0×10^{-4}	3.1×10^{-5}	4.0×10^{-5}
108	4.1×10^{-5}	2.0×10^{-5}	4.0×10^{-5}
109	1.2×10^{-4}	6.8×10^{-6}	-
111	2.0×10^{-4} (0% Inhi- bition)	2.0×10^{-4} (0% Inhi- bition)	-
116	5.0×10^{-4} (41% Inhi- bition)	5.3×10^{-4}	-
119	5.5×10^{-4}	5.0×10^{-4}	-
120	8.0×10^{-4}	7.5×10^{-4}	-
121	6.7×10^{-4}	1.2×10^{-3}	-
124	1.6×10^{-4}	1.9×10^{-4}	-
128	1.6×10^{-4}	5.0×10^{-4}	-
132	2.4×10^{-5}	7.5×10^{-5}	-
141	1.5×10^{-5}	6.1×10^{-6}	1.3×10^{-5}
142	2.8×10^{-4}	9.3×10^{-5}	-
145	3.9×10^{-5}	9.3×10^{-6}	1.9×10^{-5}
146	1.8×10^{-4}	3.1×10^{-4}	-
154	1.2×10^{-5}	4.5×10^{-5}	-
156	1.6×10^{-5}	1.7×10^{-5}	3.6×10^{-5}
158	1.0×10^{-4}	1.6×10^{-4}	-




Table V (Evaluation Results of Present Compounds)






Compound No.	Thrombin		Plasma Kallikrein		Urokinase
	S-2238	Fibrinogen	Trypsin	S-2302	
62	5.0×10^{-5} (0% Inhibition)	5.0×10^{-5} (0% Inhibition)	1.5×10^{-4}	-	-
80	1.0×10^{-4} (24% Inhibition)	1.0×10^{-4} (0% Inhibition)	3.3×10^{-4}	-	-
89	2.0×10^{-5} (22% Inhibition)	4.0×10^{-5} (0% Inhibition)	3.5×10^{-4} (0% Inhibition)	-	-
104	1.0×10^{-4} (0% Inhibition)	1.0×10^{-4} (0% Inhibition)	2.4×10^{-5}	7.6×10^{-5}	1.1×10^{-4}
108	1.0×10^{-3} (23% Inhibition)	1.0×10^{-3} (0% Inhibition)	6.4×10^{-6}	1.5×10^{-5}	8.5×10^{-6}
109	4.0×10^{-4} (0% Inhibition)	3.0×10^{-4} (0% Inhibition)	1.2×10^{-5}	2.9×10^{-5}	4.5×10^{-5}
111	-	-	-	2.0×10^{-4} (0% Inhibition)	-
116	5.0×10^{-5} (0% Inhibition)	1.0×10^{-3} (0% Inhibition)	5.0×10^{-5}	5.0×10^{-5}	1.3×10^{-4}
141	5.0×10^{-4} (0% Inhibition)	1.0×10^{-4} (0% Inhibition)	1.5×10^{-6}	8.5×10^{-5}	1.7×10^{-5}

CLAIMS

1. A lysine derivative having the general formula:

A-Y-Lys-B (L-form) (A)

wherein A represents , , ,



25 wherein X and X' independently represent hydrogen, halogen, alkyl, cycloalkyl, alkoxy, aryloxy, dialkylamino, alkylcarbonylamino, arylcarbonylamino, and n_1 is an integer of 3 to 6, n_2 is an integer of 1 to 3, and n_3 is an integer of 0 to 3;

30 Y represents SO_2 or CO ;

$(\text{CH}_2)_4\text{-NH}_2$
-Lys- represents -NH-CH-CO- ;

35 B represents NR^1R^2 , NZ^{W} , or tetrahydroquinolyl, wherein R^1 and R^2 independently represents hydrogen provided that both R^1 and R^2 cannot be hydrogen at the same time; alkyl substituted

with carboxyl, alkoxycarbonyl, phenyl, hydroxyphenyl, or benzoyl; cycloalkyl which may be substituted with arylcarbonyl; cycloalkyl-alkyl which may be substituted with carboxyl, arylcarbonyl, or aralkyloxycarbonyl; phenyl which may be substituted with halogen, nitro, cyano, trifluoromethyl, alkyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, phenylalkyl which may be further substituted with dialkylamino, alkylcarbonyl, phenylalkenyl which may be further substituted with dialkylamino, phenoxy, phenylcarbonyl which may be further substituted with an amino, dialkylamino, alkoxycarbonyl, or nitro group, pyridylmethyl, phenyl hydroxyalkyl, alkylsulfonyl, or alkoxycarbonyl alkylaminocarbonyl; coumaryl which may be substituted with alkyl; quinolyl; adamantyl; norbornyl; or tetrahydronaphthyl; and

Z is $-(CH_2)_{m_1}-CH(CH_2)_{m_2}-$ or $-(CH_2)_{m_1}-N-(CH_2)_{m_2}-$;
W is hydrogen; hydroxyl; carboxyl;

aminocarbonyl; alkyl; alkoxycarbonyl; phenyl; phenylalkyl which may be substituted with dialkylamino; or phenyl-carbonyl which may be substituted with alkoxycarbonyl or tetrahydroquinolyl; and

$m_1 + m_2 = 3$ or 4 ;
or the pharmaceutically acceptable salt

thereof.

2. A lysine derivative as claimed in claim 1, wherein the pharmaceutically acceptable salt is at least one salt selected from the group consisting of hydrochloride, hydrobromide, sulfate, nitrate, phosphate, oxalate, succinate, malate, citrate, lactate, benzene sulfonate, toluene sulfonate, and methane sulfonate.

3. A proteinase inhibitor comprising as an essential component the lysine derivative of claim 1 or the pharmaceutically acceptable salt thereof.

4. A proteinase inhibitor as claimed in claim 3, wherein the pharmaceutically acceptable salt is at least one salt selected from the group consisting of

hydrochloride, hydrobromide, sulfate, nitrate, phosphate, oxalate, succinate, malate, citrate, lactate, benzene sulfonate, toluene sulfonate, and methane sulfonate.